Article
Ocugen doses first patient in phase 1 trial of OCU200 for treatment of diabetic macular edema
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Cost-effectiveness of AI pediatric eye screening
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
City Therapeutics and Bausch + Lomb partner on geographic atrophy treatment candidate
How food choices may affect non-refractive visual impairment